<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>28(23)</volume><submitter>Liu R</submitter><pubmed_abstract>Glycogen synthase kinase 3beta (GSK-3beta) represses cell cycle progression by directly phosphorylating cyclin D1 and indirectly regulating cyclin D1 transcription by inhibiting Wnt signaling. Recently, we reported that the Epm2a-encoded laforin is a GSK-3beta phosphatase and a tumor suppressor. The cellular mechanism for its tumor suppression remains unknown. Using ex vivo thymocytes and primary embryonic fibroblasts from Epm2a(-/-) mice, we show here a general function of laforin in the cell cycle regulation and repression of cyclin D1 expression. Moreover, targeted mutation of Epm2a increased the phosphorylation of Ser9 on GSK-3beta while having no effect on the phosphorylation of Ser21 on GSK-3alpha. In the GSK-3beta(+/+) but not the GSK-3beta(-/-) cells, Epm2a small interfering RNA significantly enhanced cell growth. Consistent with an increased level of cyclin D1, the phosphorylation of retinoblastoma protein (Rb) and the levels of Rb-E2F-regulated genes cyclin A, cyclin E, MCM3, and PCNA are also elevated. Inhibitors of GSK-3beta selectively increased the cell growth of Epm2a(+/+) but not of Epm2a(-/-) cells. Taken together, our data demonstrate that laforin is a selective phosphatase for GSK-3beta and regulates cell cycle progression by GSK-3beta-dependent mechanisms. These data provide a cellular basis for the tumor suppression activity of laforin.</pubmed_abstract><journal>Molecular and cellular biology</journal><pagination>7236-44</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2593373</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Laforin negatively regulates cell cycle progression through glycogen synthase kinase 3beta-dependent mechanisms.</pubmed_title><pmcid>PMC2593373</pmcid><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Zhou P</pubmed_authors><pubmed_authors>Liu R</pubmed_authors><pubmed_authors>Minassian BA</pubmed_authors><pubmed_authors>Wang X</pubmed_authors><pubmed_authors>Turnbull J</pubmed_authors><pubmed_authors>Zheng P</pubmed_authors><pubmed_authors>Chen C</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Wang L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Laforin negatively regulates cell cycle progression through glycogen synthase kinase 3beta-dependent mechanisms.</name><description>Glycogen synthase kinase 3beta (GSK-3beta) represses cell cycle progression by directly phosphorylating cyclin D1 and indirectly regulating cyclin D1 transcription by inhibiting Wnt signaling. Recently, we reported that the Epm2a-encoded laforin is a GSK-3beta phosphatase and a tumor suppressor. The cellular mechanism for its tumor suppression remains unknown. Using ex vivo thymocytes and primary embryonic fibroblasts from Epm2a(-/-) mice, we show here a general function of laforin in the cell cycle regulation and repression of cyclin D1 expression. Moreover, targeted mutation of Epm2a increased the phosphorylation of Ser9 on GSK-3beta while having no effect on the phosphorylation of Ser21 on GSK-3alpha. In the GSK-3beta(+/+) but not the GSK-3beta(-/-) cells, Epm2a small interfering RNA significantly enhanced cell growth. Consistent with an increased level of cyclin D1, the phosphorylation of retinoblastoma protein (Rb) and the levels of Rb-E2F-regulated genes cyclin A, cyclin E, MCM3, and PCNA are also elevated. Inhibitors of GSK-3beta selectively increased the cell growth of Epm2a(+/+) but not of Epm2a(-/-) cells. Taken together, our data demonstrate that laforin is a selective phosphatase for GSK-3beta and regulates cell cycle progression by GSK-3beta-dependent mechanisms. These data provide a cellular basis for the tumor suppression activity of laforin.</description><dates><release>2008-01-01T00:00:00Z</release><publication>2008 Dec</publication><modification>2025-04-04T13:39:21.061Z</modification><creation>2019-03-27T00:19:37Z</creation></dates><accession>S-EPMC2593373</accession><cross_references><pubmed>18824542</pubmed><doi>10.1128/MCB.01334-08</doi><doi>10.1128/mcb.01334-08</doi></cross_references></HashMap>